Life Sciences

Analysis Finds Reporting Delays For Serious Adverse Events


According to a recent research letter in the Journal of the American Medical Association (JAMA), an analysis of serious adverse event (SAE) reports from January 1, 2004 and June 30, 2014 (with certain exclusions) concluded that drug companies were more likely to delay the reporting of such instances within the required 15 calendar days, if death was the patient outcome. Close to 10% of SAEs were not reported on time. 

Life Sciences - How Artificial Intelligence Can Enhance the Clinical Data Review and Cleaning Process
How Artificial Intelligence Can Enhance the Clinical Data Review and Cleaning Process

This guide analyzes how artificial intelligence – including machine learning – can be used by pharmaceutical and medical device companies to improve the clinical data review and cleansing process.

Get the Guide

While the reasons for the reporting delays aren’t clear, it’s plausible that they’re caused by the more comprehensive verification process that’s required for SAEs like patient death. The ramifications of the inaccurate reporting of SAEs and/or drug-event connections could be devastating to patients, as well as companies. For example, safe medications could prematurely be withdrawn from the market.

The analysis also suggests that reporting SAEs directly to the FDA, rather than to drug companies, could help companies better meet the regulatory reporting requirements.

To read the letter in JAMA, click here.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Eugene Sefanov

Sr. Marketing Manager, Industries, Perficient

More from this Author

Subscribe to the Weekly Blog Digest:

Sign Up
Follow Us